All Is Not Lost: AstraZeneca plc Has Less Than 48hrs To Cut A Deal With Pfizer

AstraZeneca plc (LON: AZN) has until Monday to negotiate a deal with Pfizer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When AstraZeneca‘s (LSE: AZN) (NYSE: AZN.US) management rebuffed Pfizer‘s $120bn, or £55 per share offer, some investors celebrated but others expressed frustration.

Around 10% of Astra’s shareholders have publicly backed the board’s decision to reject Pfizer’s offer. However, another 10% of the company’s investors are now calling for the company to reopen negotiations with Pfizer and push for a better deal.

The group spearheading the drive to get Pfizer and Astra back to the negotiation table, is headed by Astra’s sixth largest shareholder, Legal & General Group, one of the UK’s largest pension fund managers. 

It’s not over yet

There is still time for the two companies to make a deal, which is now a real possibility as shareholder cries for further negotiation are getting louder by the day. 

Still, due to the nature of Pfizer’s offer, under UK takeover rules, the two companies only have until Monday to enter talks or the offer will expire. If the offer does expire, then Pfizer is not allowed to approach Astra with another offer for at least six months. 

Unfortunately, Monday is a bank holiday both here and across the pond, so it might be a long weekend for both parties if they do decide to head back to the table and thrash out a deal. 

It’s not as simple as hiking the price

Realistically, the chances of a deal are slim. Astra’s management has stated the minimum price that they would accept from Pfizer is £59 per share but under takeover rules, Pfizer is not allowed to increase its offer to this level.

Nevertheless, Pfizer can change the structure of the deal, in order to make it more attractive for Astra’s shareholders. For example, Pfizer can raise the cash element of the deal, which at present stands at only 45%. If Pfizer upped its offering to £55 per share in cash, it’s possible that the majority of the company’s shareholders would be willing to make a deal.

Additionally, although Pfizer cannot increase its offer, the company can add what’s known as a contingent-value right. With a contingent-value right, Astra’s investors could receive an additional payout, either cash or shares, in the event of an experimental drug being approved.

Not only would this type of deal allow Pfizer to raise its offer for Astra but it would also work as a sweetener for Astra’s investors, some of whom believe that they would miss out on the company’s future potential if it was acquired.

However, one thing is certain, Pfizer is not allowed to increase the value of its total offer above £55 per share, so any deal will take time to negotiate. But will the two companies have time to cut a deal? 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »